high risk to be non compliant. Patients declaring good compliance, aged <77.5, with a good patient-clinician relationship were likely to be compliant. CONCLUSIONS: When medical data were not associated with compliance, patient reported outcome might help at identifying glaucoma treatment compliance issues. Treatment compliance is a complex concept, including several dimensions with interactions. EDSQ demonstrated some abilities at identifying non compliant patients. Age, declared compliance and satisfaction with patient-clinician relationship are dimensions that would be worth being explored before switching a glaucoma treatment due to lack of intra-ocular pressure control. It has long been suspected that treatment compliance is affected by HRQoL. The aim of this study is to assess how compliance is related to GSS scores and other treatment variables in Glaucoma. METHODS: An observational study was carried out gathering information on the Spanish version of the Glaucoma Symptom Scale (GSS), three compliance scales (MoriskyGreen, Haynes-Sackett, & Batalla) and information about disease severity and treatment. Concordance between adherence scales was first assessed. Using the Morisky-Green score as target criteria, a segmentation tree was tested in order to forecast compliance probability. CHAID growing algorithm was used. RESULTS: A sample of 367 patients was recruited with an average age of 68 (Ϯ12.1) years from which 57% were females. Most patients (87.7%) were diagnosed of glaucoma, 10.5% were diagnosed of glaucoma and severe PIO and 1.8% presented sever PIO alone. Agreement between adherence scales was poor with a marked superiority of the Morisky-Green questionnaire. The most significant segmentation variable was GSS score, followed by age, glaucoma severity (as assessed by the clinician), number of treatment drugs, and number treatment of drops. Interaction was found between number of drops and other variables in the model. CONCLUSIONS: Using the tree model developed it is possible to predict compliance probability. Self perceived symptom discomfort is found to be the best predictor. Additional evidences of GSS construct validity as a measure of HRQoL have been found. To assess the effect of moderate to severe psoriasis on quality of life (QoL) in Spanish patients. METHODS: An observational study was conducted at 132 centers in Spain which included 10 consecutive patients with moderate to severe psoriasis, defined as: 1) patients with Body Surface Area >= 10 or 2) Psoriasis Area and Severity Index (PASI) >= 10 or 3) Physician's Global Assessment >= 5 or 4) patients receiving systemic treatment. Demographic data, medical history, treatments, occupational impairment, current state of the disease, resource use, and QoL using the Dermatology Life Quality Index (DLQI) and other questionnaires were collected. The DLQI is a self-administered questionnaire with 10 questions measuring 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. DLQI results are shown as mean scores and percentages (mean value obtained over the maximum score of the domain). RESULTS: A total of 1307 (1141 with complete data) patients with moderate to severe psoriasis fulfilled the inclusion criteria for the present study (38% female), with a mean age of 45.7 Ϯ 0.9 (mean Ϯ SD) years, mean duration of the disease of 23.3 Ϯ 2.3 years and mean PASI score of 13.1 Ϯ 0.3. The mean DLQI score was 8.7 Ϯ 0.2, meaning a moderate effect of psoriasis on patient life. Highest mean scores (worst) were obtained in symptoms and feelings (2.7, 45%) and treatment (1.0, 33%) domains and lowest mean scores were obtained in personal relationships (1.1, 18%) and work and school (0.7, 23%) domains. Mean scores for daily activities and leisure were 1.7 (28%) and 1.6 (26%) respectively. CONCLU-SIONS: Moderate to severe psoriasis has a negative impact on patient QoL. A more intensive and integrated approach to these patients should be considered to achieve a smaller impact of psoriasis on patients' quality of life.
To assess the effect of moderate to severe psoriasis on quality of life (QoL) in Spanish patients. METHODS: An observational study was conducted at 132 centers in Spain which included 10 consecutive patients with moderate to severe psoriasis, defined as: 1) patients with Body Surface Area >= 10 or 2) Psoriasis Area and Severity Index (PASI) >= 10 or 3) Physician's Global Assessment >= 5 or 4) patients receiving systemic treatment. Demographic data, medical history, treatments, occupational impairment, current state of the disease, resource use, and QoL using the Dermatology Life Quality Index (DLQI) and other questionnaires were collected. The DLQI is a self-administered questionnaire with 10 questions measuring 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. DLQI results are shown as mean scores and percentages (mean value obtained over the maximum score of the domain). RESULTS: A total of 1307 (1141 with complete data) patients with moderate to severe psoriasis fulfilled the inclusion criteria for the present study (38% female), with a mean age of 45.7 Ϯ 0.9 (mean Ϯ SD) years, mean duration of the disease of 23.3 Ϯ 2.3 years and mean PASI score of 13.1 Ϯ 0.3. The mean DLQI score was 8.7 Ϯ 0.2, meaning a moderate effect of psoriasis on patient life. Highest mean scores (worst) were obtained in symptoms and feelings (2.7, 45%) and treatment (1.0, 33%) domains and lowest mean scores were obtained in personal relationships (1.1, 18%) and work and school (0.7, 23%) domains. Mean scores for daily activities and leisure were 1.7 (28%) and 1.6 (26%) respectively. CONCLU-SIONS: Moderate to severe psoriasis has a negative impact on patient QoL. A more intensive and integrated approach to these patients should be considered to achieve a smaller impact of psoriasis on patients' quality of life. To confirm the reliability of quality-of-life (QOL) assessments in a randomized controlled trial (RCT), we investigated the changes in internal standards as a representative of 'response shift (RS)'. METHODS: One-hundred and three patients with age-related maculopathy in Japan were randomized to the intervention group and the control group. The intervention group received a standardized low vision care program for 6 months. For ethical considerations, low vision care was also provided for applicants in the control group after 6 months. We assessed visual function-related QOL using the Japanese version of the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) at baseline, 6-, and 12-months. We asked the patients to answer an additional questionnaire to investigate the changes in internal standards at 6-and 12-months which inquired about QOL at baseline (then-test). This questionnaire included 7 items selected from the VFQ-25 as the representatives of major 7
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domains (general vision [GV], near vision [NV], distance vision [DV], social function [SF], mental health [MH], role limitations [RL], and dependency [DP])
. RESULTS: Fiftyfour patients at 6-months and 52 patients at 12-months completed the then-test questionnaire in addition to the VFQ-25. Regardless of the direction of change (improved or deteriorated) in scores, the then-test results tended to decrease the difference of the scores. That is, then-test scores tended to be higher than baseline scores in the case of improvement, and tended to be lower than baseline scores in the case of deterioration. The statistically significant difference was observed between pre-and Abstracts A621 then-test scores only in the item of NV (P < 0.01). This was consistent in the additional analyses divided into the two RCT arms on the whole. CONCLUSIONS: The results of this study suggest that we can rely on the QOL assessment results in RCTs without worrying too much about RS. University of Utah Health Sciences Center, Salt Lake City, UT, USA OBJECTIVES: The objective of this analysis was to examine the impact of ustekinumab on health related quality of life (HRQoL) in psoriasis patients. METHODS: 766 patients were enrolled in the PHOENIX I trial. Patients were randomized to placebo, ustekinumab 45 mg, or ustekinumab 90 mg. Patients received ustekinumab at baseline, week 4, and q12w thereafter. Patients randomized to placebo received placebo at baseline and week 4, and ustekinumab 45 mg or 90 mg after cross-over at week 12. HRQoL were assessed using the SF-36 and Dermatology Life Quality Index (DLQI). RESULTS: Baseline SF-36 and DLQI scores were similar among treatment groups with a mean PCS score of 47.9, mean MCS score of 49.8, and mean DLQI score of 11.5. Compared with the placebo group, patients in each ustekinumab group had significantly greater improvements from baseline in both the PCS (2.0 and 3.2, vs. -0.5, p < 0.001) and MCS scores (2.1 and 2.5 vs. -1.3, p < 0.001) at week 12. All 8 domains of the SF-36 showed statistically significant improvements (p < 0.05) in the combined ustekinumab group versus placebo at week 12. At week 12, the mean change from baseline in DLQI was -8.0 for the 45 mg group and -8.7 for the 90 mg group versus -0.6 for the placebo group (each p < 0.001 vs. placebo). A greater proportion of patients in each ustekinumab group than in the placebo group achieved a clinically meaningful improvement in PCS and MCS scores (Ն5-point improvement), and a DLQI score of 0 or 1 at week 12. These improvements observed in the ustekinumab groups were maintained through week 40. Patients in the placebo group who crossed-over to ustekinumab at week 12 achieved improvements in PCS, MCS and DLQI scores at week 40 that were similar in magnitude to those observed in patients initially randomized to ustekinumab. CONCLUSIONS: Ustekinumab treatment significantly improves overall and diseasespecific quality of life in moderate to severe psoriasis patients.
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